Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Asian dose-escalation and expansion study of BI 765049 alone and with ezabenlimab in B7-H6-expressing solid tumors
jRCT2031230596Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 1, open-label trial of BI 765049 and ezabenlimab in gastric cancer (GC), colorectal cancer (CRC), pancreatic adenocarcinoma (PDAC) and 3 more (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Dose-limiting toxicities and Objective response rate by RECIST v1.1. Started Feb 2024; status: completed.
02
Drugs
BI 765049ezabenlimab
03
Conditions
gastric cancer (GC)colorectal cancer (CRC)pancreatic adenocarcinoma (PDAC)hepatocellular carcinoma (HCC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCT2031230596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230596.